Ocular HSV: A leading
cause of blindness4

Annually in the United States, there are:

There are approximately 20,000 new cases of ocular HSV annually in the United States

~20,000

new cases
of ocular HSV

There are greater than 28,000 cases of recurrence annually in the United States

>28,000

cases
of recurrence

There are approximately 500,000 people living with HSV-related ocular disease in the United States

~500,000

people WITH
HSV-related
ocular disease

INDICATION

ZIRGAN (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated
for the treatment of acute herpetic keratitis (dendritic ulcers).

ZIRGAN Targets HSV-Infected Cells,
Not Healthy Corneal Cells

ZIRGAN contains the active ingredient ganciclovir, which is a guanosine derivative that, upon phosphorylation, inhibits DNA replication by herpes simplex viruses (HSV).2

Ganciclovir is transformed by viral and cellular thymidine kinases to ganciclovir triphosphate, which works as an antiviral agent by inhibiting the synthesis of viral DNA in 2 ways2:

  • Competitive inhibition of viral DNA polymerase
  • Direct incorporation into viral primer strand DNA, resulting in DNA chain termination and prevention of replication

In uninfected cells, cellular thymidine kinase is unable to substantially phosphorylate the ganciclovir prodrug, and cellular DNA polymerase is less sensitive to ganciclovir inhibition. This contributes to the relative lack of ganciclovir cytotoxicity in healthy cells.5

See ZIRGAN in action

Watch the MOA video

X
 
 
 
 
 
 
 
 
 
 
Gel formulation allows for increased exposure of ZIRGAN at the site of action on the ocular surface.

Formulation

Gel formulation allows for increased exposure of
ZIRGAN at the site of action on the ocular surface.6

Please see Important Safety Information below.

ZIRGAN dosing and administration for treatment of dendritic ulcers

ZIRGAN Dosing
and Handling

  • Recommended dosing regimen2:
    • One drop in the affected eye 5 times
      per day (approximately every 3 hours
      while awake) until the corneal ulcer heals
    • Followed by 1 drop 3 times per day for
      7 days
  • ZIRGAN is supplied as 5 grams of a topical
    ophthalmic gel containing 0.15% of
    ganciclovir in a polycoated aluminum tube.
    NDC number: 24208-535-35
  • There is no need for refrigeration (store between 59°F and 77°F). Do not freeze2
ZIRGAN dosing and administration for treatment of dendritic ulcers

Help Your
Eligible Patients
Save on ZIRGAN†

With the Bausch + Lomb Access Program, eligible patients can save on their ZIRGAN prescriptions.†

This program offers savings up to $35 for eligible commercially insured patients and up to $135 off for eligible uninsured patients.†

Patients can download and activate a
Bausch + Lomb Access card by visiting bauschaccessprogram.com.

  • Patients who receive a physical co-pay card in office can activate online at www.blsavings.com, on the phone by calling 1-866-693-4880, or by texting BLSAVINGS to 24109‡
  • Once the card has been downloaded or activated, patients can take it to Walgreens or a participating independent pharmacy to pick up their prescription

†Terms and conditions apply. See eligibility
criteria and terms and conditions at bauschaccessprogram.com.

‡Message and data rates may apply. Full
terms can be viewed at https://bauschaccess.copaysavingsprogram.com/sms-terms.

Bausch + Lomb Access Program card for prescription savings on ZIRGAN
ZIRGAN ganciclovir ophthalmic gel samples

Interested in ZIRGAN samples?

The Bausch + Lomb Sample Vault is an easy-to-use and secure way to order Bausch + Lomb
product samples and branded information to be delivered to your office.

Request samples
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

References: 1. Foster CS. Ganciclovir gel—a new topical treatment for herpetic keratitis. US Ophthalmic Rev. 2007;3(1):52-56. 2. ZIRGAN [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2016. 3. Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). Drugs. 2011;71(5):603-610. 4. Wang JC, Ritterband DC. Herpes simplex virus (HSV) keratitis. Medscape website. https://emedicine.medscape.com/article/1194268-overview#a6. Updated November 3, 2017. Accessed August 16, 2018. 5. St. Clair MH, Lambe CU, Furman PA. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob Agents Chemother. 1987;31(6):844-849. 6. Chou TY, Hong BY. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag. 2014;10:665-681.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.

 
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below:

I am a healthcare professional
in the U.S.
I am not a
healthcare professional